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ABSTRACT
Objective: To demonstrate how the optimal decision and
level of uncertainty associated with that decision, can be
presented when assessing the cost-effectiveness of multiple
options. To explore and explain potentially counterintuitive
results that can arise when analyzing multiple options.
Methods: A template was created, based on the assumption
of multivariate normality, in order to replicate a previous
analysis that compared the cost-effectiveness of multiple
options. We used this template to explain some of the differ-
ent shapes that the cost-effectiveness acceptability curve
(CEAC), cost-effectiveness acceptability frontier (CEAF), and
expected value of perfection information (EVPI) may take,
with changing correlation structure and variance between the
multiple options.
Results: We show that it is possible for 1) an option that
is subject to extended dominance to have the highest pro-
bability of being cost-effective for some values of the cost-
effectiveness threshold; 2) the most cost-effective (optimal)
option to never have the highest probability of being
cost-effective; and 3) the EVPI to increase when the probabil-
ity of making the wrong decision decreases. Changing the
correlation structure between multiple options did not
change the presentation of results on the cost-effectiveness
plane.
Conclusion: The cost-effectiveness plane has limited use in
representing the uncertainty surrounding multiple options as
it cannot represent correlation between the options. CEACs
can represent decision uncertainty, but should not be used to
determine the optimal decision. Instead, the CEAF shows the
decision uncertainty surrounding the optimal choice and this
can be augmented by the EVPI to show the potential gains to
further research.
Keywords: cost-effectiveness acceptability curve (CEAC),
cost-effectiveness acceptability frontier (CEAF), cost-
effectiveness plane, expected value of perfect information
(EVPI), uncertainty.
Introduction
The cost-effectiveness acceptability curve (CEAC) was
introduced as a method to represent uncertainty, and is
often used to present the results of cost-effectiveness
analysis [1–4]. However, it is possible that the CEAC
may be misinterpreted [5,6]. This possibility is high-
lighted by the fact that one might (incorrectly) infer,
from one paper [7], that CEACs show the value at
which each option becomes the optimal choice, and
from another paper [8], that they show the probability
that one option dominates another option. There is
a similar possibility that the purpose of the cost-
effectiveness acceptability frontier (CEAF) may also be
misinterpreted. This is highlighted by the fact that,
when purportedly constructing the CEAF, some ana-
lysts [8,9] have plotted the probability of cost-
effectiveness for many options, rather than just the
optimal option, and used the termCEAF to describe this
mode of presentation. In light of these issues, we seek to
demonstrate how the CEAC and CEAF should be con-
structed, what they should and should not be used for,
and in doing so, how the optimal decision can be
presented, along with levels of uncertainty.
In order to illustrate the above, we present (and
make available online) a spreadsheet-based template
that can be used to represent uncertainty in the deci-
sion among a number of mutually exclusive treatment
options. We then employ this template to explain two
entirely possible results that may nonetheless appear
counterintuitive. First, that an option that was subject
to extended dominance [10,11] can have the highest
probability of being cost-effective. Second, that the
optimal option (as it provided the greatest beneﬁt for
a given cost) may not have the highest probability
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of being cost-effective for any value of the cost-
effectiveness threshold. Both of these situations were
apparent in the results presented by Goeree et al. [1],
and this study serves as a practical example to show
why such results are in fact valid, and how decision
uncertainty in such situations should be presented and
interpreted.
The paper is structured as follows: First, we provide
an overview of the main principles of cost-effectiveness
analyses and illustrate the importance of the CEAC,
CEAF, and expected value of perfect information
(EVPI). Second, we outline a template that can be used
by others and is used here to demonstrate how to
calculate CEACs, the CEAF, and the EVPI in the pres-
ence of multiple options. Finally, this template is used
to illustrate how different assumptions about the
correlation structure and the variances of the model
outputs can inﬂuence the shape of the resulting
CEACs, CEAF, and EVPI, thus demonstrating why the
two potentially counterintuitive results occurred in the
study by Goeree et al. [1].
Principles of Cost-Effectiveness Analyses
When making decisions about the allocation of scarce
health-care resources, it has been argued that two
questions are fundamental [12–14]. First, which
option is estimated to be cost-effective, on the basis of
existing evidence? Second, should further research be
undertaken in order to reduce the level of uncertainty
associated with that decision?
In order to answer the ﬁrst question, one seeks to
identify the option that is expected to provide the
highest level of beneﬁt for a given level of cost, i.e.,
the aim is to maximize health subject to a budget
constraint [15–17]. In the case of mutually exclusive
options, this involves the calculation of the incremen-
tal cost-effectiveness ratio (ICER) of each option rela-
tive to the next best treatment option, and the selection
of the option that has the highest ICER below the
cost-effectiveness threshold as the optimal option.
When calculating the ICER, it is important to identify,
and exclude, those options that are dominated (more
costly and less effective than another option) and those
that are subject to extended dominance (combinations
of other options can provide a higher level of beneﬁt
for the same cost) [18].
One of the most common ways of presenting the
results of cost-effectiveness analysis is on the cost-
effectiveness plane [19], where the effects are measured
on the horizontal axis and costs are measured on the
vertical axis. By plotting the mean cost and mean effect
of each option and connecting each cost-effective (i.e.,
nondominated) option with the next less effective
option, it is possible to display the efﬁciency frontier
for these options [1,20]. Thus, though the cost-
effectiveness plane can answer the ﬁrst fundamental
question, by identifying the option that provides the
highest level of expected beneﬁt at different levels of
cost, it has been argued that the plane fails to fully
represent the level of uncertainty associated with the
estimated cost-effectiveness of an option in a graphical
manner [21]. As a consequence of this, the CEAC was
developed. The CEAC is constructed by plotting (for
each option) the proportion of the cost and effect pairs
that are cost-effective for a range of values of the
cost-effectiveness threshold [22]. Thus, uncertainty is
characterized by estimating the probability that an
option is cost-effective at different levels of the cost-
effectiveness threshold, where this is undertaken for all
possible options. Fenwick et al. [17], however, have
shown that an option that had the highest probability
of being cost-effective need not necessarily have the
highest expected net beneﬁt, and for this reason, the
CEAC should not be used to identify the optimal treat-
ment option. Instead, they propose the use of the
CEAF [17], which plots the uncertainty associated
with the optimal option, for different values of the
cost-effectiveness threshold. This is equivalent to plot-
ting each CEAC over the range of values for the cost-
effectiveness threshold for which each option is
estimated to be the most cost-effective, i.e., has the
highest ICER that falls below the threshold [17].
Finally, in order to inform the second fundamental
question concerning the decision of whether to under-
take further research, the EVPI can be calculated. The
EVPI gives an upper bound on the value of undertak-
ing further research in order to eliminate the uncer-
tainty surrounding the decision about which option is
optimal for different levels of the cost-effectiveness
threshold [20,23]. The EVPI is dependent upon both
the probability of a wrong decision being made (as
shown by the CEAF), but also the consequences of that
wrong decision [23,24]. Further research costing less
than the EVPI only has the potential to be efﬁcient;
a sufﬁcient condition for determining the worth of
further research requires comparison of the expected
value of sample information and the costs (see [23] and
[25] for more details).
Methods
Probabilistic methods can be used to describe the uncer-
tainty associated with input parameters in a model, and
in turn, can estimate the uncertainty in the model
outputs of cost, effect, and cost-effectiveness [20]. This
equates to a Bayesian approach to cost-effectiveness
analysis because the parameters of interest are ascribed
a distribution in order to reﬂect the uncertainty con-
cerning the true value of the parameter [26]. For the
purposes of exploring potential scenarios relating to the
costs and effects of multiple options, we developed a
template (in Excel, Microsoft, Redmond, WA) that
approximates the joint distributions of the costs and
effects of multiple treatment options under the assump-
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tion of multivariate normality. As such, we seek to
provide a generic characterization of the uncertainty
associated with model outputs for the purposes of
illustration and ease of manipulation. Readers are
directed to Briggs et al. [20] for further direction on
how to characterize the uncertainty of input parameters
using probability distributions. The template, which
can be downloaded at http://www.dph.gla.ac.uk/heat,
works with up to seven different options and requires
the user to input the means and standard errors for all
options. In addition, the user also speciﬁes the correla-
tion structure between the costs and effects both within
and between options. From this information, the
variance-covariance matrix is generated and (through
the use of the Cholesky decomposition technique [20])
the template draws 1000 simulations of both the cost
and effect parameters of each option from the speciﬁed
multivariate normal distribution. Finally, using the
methods described later, the template provides esti-
mates of the CEACs, CEAF and the EVPI.
CEAC
In the case of multiple options, a separate CEAC can
be plotted for each option, where each CEAC repre-
sents the (essentially Bayesian) probability of each
option being cost-effective at different levels of the
cost-effectiveness threshold [20,27]. This probability
was estimated in the following manner: In each of the
1000 iterations, the total cost (C) and total effect (E)
was estimated for each option, and for a particular
cost-effectiveness threshold (l), the net monetary
beneﬁt (NMB) was estimated: NMB = l ¥ E - C. In
each of the 1000 iterations, the option with the highest
net beneﬁt was then identiﬁed. The probability of
being cost-effective was then equivalent to the propor-
tion of the 1000 iterations for which each option had
the highest net beneﬁt. CEACs were estimated by plot-
ting these proportions (y-axis) for different l-values
(x-axis). With regard to the claim that the CEAC
shows the probability that one option dominates
another option [8], it can be seen that this is untrue
because the CEAC is determined by the net beneﬁt of
each option and it is possible for an option to have a
higher net beneﬁt without dominating another option.
CEAF
Fenwick et al. [17] have shown that the probability of
being cost-effective cannot be used to determine the
optimal option, and that if the societal objective is to
maximize health gain, then decisions should be taken
on the basis of expected net beneﬁt, regardless of the
uncertainty (probability) associated with the decision.
Thus, the option with the highest probability of being
cost-effective (highest CEAC) at any value of the cost-
effectiveness threshold need not be the optimal option
[28]. The solution to the fact that CEACs cannot iden-
tify the optimal option is to plot the CEAF [17].
In contrast to the CEACs, the CEAF plots only the
probability that the optimal option is cost-effective (at
different l-values). Thus, it is ﬁrst necessary to identify
which option is optimal at each level of the cost-
effectiveness threshold. To do this, it is necessary to
identify the mean cost and mean effect for each option
(across each of the 1000 simulations), and to calculate
which option is optimal (has the highest expected net
beneﬁt) at different levels of l. Thus, the range of
l-values over which an option is optimal can be cal-
culated, and the “switch points” (when there is a
change in the optimal option) correspond to the ICER
between different options [17]. The lower value of the
range of values for the cost-effectiveness threshold for
which each option was optimal denotes the ICER for
that particular option, and the upper value denotes the
ICER for the next most costly option.
Once the optimal option has been identiﬁed for
each level of l, the probability of this option being
cost-effective can then be plotted (y-axis) for different
l-values (x-axis). This probability of being cost-
effective is determined by the CEAC. One minus the
probability given by the CEAF at any value of the
cost-effectiveness threshold is equivalent to the prob-
ability that a “wrong” decision will be made (the error
probability) [13]. Finally, it should be noted that
because only optimal options are represented, the
CEAF may not always correspond to the options with
the highest probability of being cost-effective.
EVPI
The EVPI (for an individual patient) is determined, for
a given l, by the difference between the expected value
with perfect information and the expected value with
current information. After calculating the expected net
beneﬁt for each option across all iterations, the ﬁrst
step is to identify the optimal option based on the
current level of information. This is the option with the
maximum expected net beneﬁt for the given level of
the cost-effectiveness threshold, as identiﬁed by the
CEAF. The second step is to identify the decision with
perfect information. This is done for every possible
realization of uncertainty (every iteration) by identify-
ing the option that maximizes net beneﬁt. Within each
iteration, the value of perfect information is equal to
the difference between the net beneﬁt of the optimal
option (from step one) and the maximum net beneﬁt
(from step two), and will equal zero when the optimal
option has the highest net beneﬁt. Finally, the EVPI is
calculated by taking the expectation over the values of
perfect information. This is equivalent to the value of
the decision when made with perfect information aver-
aged across all possible realizations of uncertainty
[14]. The EVPI was then calculated for differing
l-values and plotted on the same diagram as the
CEAF; it shows the maximum amount that one would
be willing to pay to eliminate uncertainty.
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Replication of Previous Analyses
By replicating the comparison of multiple options by
Goeree et al. [1], we sought to depict and explain both
the optimal decision and the level of uncertainty asso-
ciated with that decision. Goeree et al. [1] estimated
the cost-effectiveness of seven different management
strategies for gastroesophageal reﬂux disease, where
costs were estimated at year 2000 levels (US$), and
effects were measured in terms of quality adjusted life
years (QALYs). In order to replicate the results, for
each of the seven options, we extracted the mean cost
(and associated standard error) and mean effect (and
associated standard error) from the results of their
probabilistic analysis (which were reported for a
cohort of 1000 patients). From the results provided by
the original authors, the correlation matrix was deter-
mined and employed to construct the variance–
covariance matrix for the analysis. Initially, we
undertook a replication of the analysis undertaken by
Goeree et al. [1] (the base-case analysis). By altering
the assumptions underlying this analysis, we then ran a
series of sensitivity analyses in order to explain why
the two potentially counterintuitive results occurred
(i.e., why an option that was subject to extended domi-
nance had the highest CEAC while an optimal option
never had the highest CEAC), and showed that those
results were entirely appropriate. In the ﬁrst of these
analyses, we assumed that the costs and effects of
different options were independent, but that the rela-
tionship between costs and effects within options
remained the same. In the second analysis, we used the
original correlation matrix but made the assumption
that the variance associated with the mean cost and
mean effect of each option was one-ﬁfth of that in the
base-case (which may have occurred if the original
analysis had involved a larger sample size). Finally, the
third analysis repeated that of the second, but with the
assumption that the variance was ﬁve times greater
than that in the base-case (representing a smaller
sample size).
Results
Replication of Previous Analyses
Base-case. After constructing the variance–covariance
matrix for the analysis by Goeree et al. [1], the template
was used to replicate their analysis. The cost and
effect pairs for each of the 1000 iterations, for each
of the seven options, were ﬁrst plotted on the cost-
effectiveness plane (Fig. 1a). After determining which
options were dominated (none) and subject to extended
dominance (options C, D, and G), it was possible to
estimate the efﬁciency frontier. In Figure 1a, it can
be seen that this is composed of options B, A
(ICER = $7755, compared with B), F (ICER =
$12,183, compared with A), and E (ICER = $110,845,
compared with F)—the efﬁciency frontier is presented
for themean costs andmean effects, rather than for each
of the 1000 simulations.
The corresponding CEACs are also plotted in
Figure 1b, where it can be seen that one of the optimal
options (A) never had the highest probability of being
cost-effective. Instead, B initially had the highest prob-
ability of being cost-effective (l < $7970), followed by
D ($7970 = l < $12,540), C ($12,540 = l < $14,850),
F ($14,850 = l < $112,120), and E (l = $112,120).
Thus, options that were subject to extended domi-
nance (C and D) were also associated with the highest
probability of being cost-effective at certain levels of ë.
This provides an illustration of why CEACs should not
and cannot be used to identify the optimal option, as
has been previously shown by Fenwick et al. [17].
In order to simultaneously present the optimal
option and the level of uncertainty associated with that
option, the CEAF was plotted (Fig. 1c). The ICERs for
options A, F, and E are plotted as vertical lines in order
to demonstrate how the optimal option was identiﬁed.
Prior to the ﬁrst vertical line (l < $7755), option B
was optimal, between the ﬁrst two vertical lines
($7755 = l < $12,183), option A was optimal, fol-
lowed by option F ($12,183 = l < $110,845), and
ﬁnally, option E (l = $110,845). It should also be noted
that the CEAFmay be disjointed. This can be seen at the
ﬁrst vertical line (l = $7755), where the probability of
option B being cost-effective was 32.7%, whereas the
corresponding probability for option A was 25.8%.
Moreover, at this point, as well as the optimal option
(A) not having the highest probability of being cost-
effective, there was a 74.2% probability that option A
was not the most cost-effective option. This arose
because the optimal option was determined by the
highest expected net beneﬁt, whereas the CEAC simply
represents the proportion of iterations over which each
option had the highest net beneﬁt.
By replicating the Goeree et al. [1] analysis, it was
also possible to estimate the EVPI for an individual
patient (Fig. 1c). The EVPI was relatively low when
there was a high probability that the optimal option
was cost-effective, with local maxima when the
optimal option changed (and the probability of a
wrong decision was relatively high), e.g., at a l of
approximately $12,000 and $111,000. However, this
was not always the case, as when the optimal option
changed from B to A there was a point of inﬂexion, but
the EVPI continued to increase. This arose, despite
there being a local maxima in the error probability,
because the falling probability of making an incorrect
decision was outweighed by the increasing conse-
quences of a wrong decision. Finally, it should be noted
that at high levels of the cost-effectiveness threshold,
the EVPI fell to virtually zero. This was because of
virtually nonexistent uncertainty at these levels of l,
where option E had a high probability of being
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Figure 1 Replication of the analysis by Goeree et al. [1]. Results are presented in terms of the cost-effectiveness plane (a), cost-effectiveness acceptability
curves (b), and the cost-effectiveness acceptability frontier and the expected value of perfect information (EVPI) (c).
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cost-effective because of strong evidence that it was the
most effective option.
Sensitivity analysis. When the analyses by Goeree
et al. [1] were replicated, with the assumption that the
costs and effects between options were independent,
the cost-effectiveness plane (Fig. 2a) was visually the
same as in the base-case analyses (see Fig. 1a), because
near identical cost and effect pairs (within options)
were drawn in both of these probabilistic analyses.
Thus, the ICERs were very similar to that in the base-
case analyses. Conversely, the CEACs changed, with
the curves tending to converge—those options that
previously had the highest probability of being cost-
effective, for a particular l, tended to have a lower
probability of being cost-effective, and other options
tended to have a higher probability of being cost-
effective. Importantly, this meant that option A (which
was the optimal option between a l of $7755 and
$12,183) now had the highest probability of being
cost-effective for a small range of l-values, and option
C (which was subject to extended dominance) no
longer had the highest probability of cost-effectiveness
over any threshold value. Here, for reasons of brevity,
rather than plotting the CEACs in the traditional
manner (as in Fig. 1b), they have been plotted on the
same diagram as the CEAF and EVPI. In Figure 2b, the
CEACs are plotted, where the (bold) continuous
section of the CEAC denotes the range of l-values over
which each option was optimal, and the (lighter)
dashed section of the CEAC denotes the range of
l-values over which each option did not provide the
highest expected net beneﬁt.
In the Goeree et al. [1] analysis, these two poten-
tially counterintuitive results arose because all the
options were positively correlated. Consequently,
when, for example, option B had a low net beneﬁt in a
particular iteration, it was likely that in the same itera-
tion, other options would also have a low net beneﬁt,
and at low levels of l, this meant that option B had
the highest net beneﬁt in a high proportion of itera-
tions (and thereby a high CEAC). Conversely, when
the options were assumed to be independent, when
option B had a low net beneﬁt, then there was a higher
chance of another option having a higher net beneﬁt,
in the same iteration, and option B thereby had the
highest net beneﬁt in a lower proportion of iterations.
The assumption that the costs and effects between
options were independent also changed the CEAF
(Fig. 2b), where the optimal options tended to have a
lower probability of being cost-effective, and the EVPI
(Fig. 2b), which also tended to be higher. Here, as in
Figure 1c, the CEAF was again constructed by plotting
the CEAC, as a continuous line, over the range of
l-values over which each option had the highest
expected net beneﬁt. It should also be noted that the
EVPI even increased when the probability of the
optimal option being cost-effective increased, e.g., at
a l of $12,000; in the base-case the EVPI was 41.4
when option A had a 17.9% probability of being cost-
effective, yet it rose to 107.4 when the options were
assumed to be independent and the probability of
option A being cost-effective increased to 19.8%. This
change in the EVPI can be explained by the fact that
when option B, for example, had a high net beneﬁt in
a particular iteration in the base-case (independent)
analysis, it was more (less) likely that other options
would also have a high net beneﬁt. Thus, in the base-
case the consequences of the wrong decision (repre-
sented by the incremental net beneﬁt) were estimated
to be less than in the analysis, where the options were
assumed to be independent.
The ﬁnal two analyses had the same correlation
structure as the base-case, but had differing levels of
variance. In both analyses, the cost and effect pairs for
each option were centered around the same means,
and thereby ICERs, but the pairs were more condensed
when the level of variation was reduced by a factor of
ﬁve (Fig. 3a) and more spread out when the variation
was inﬂated by a factor of ﬁve (Fig. 4a). Looking at
the CEACs, reducing the level of variation tended to
increase the probability of optimal options being cost-
effective, at the expense of the probability associated
with other options (Fig. 3b). Indeed, option A now had
the highest probability of being cost-effective over a
reasonable range of l-values, and options C/D only
brieﬂy did so ($11,690  l < $12,950).
In the Goeree et al. [1] analysis, the two poten-
tially counterintuitive results arose because options C
and D, which were subject to extended dominance,
had relatively high levels of variation in net beneﬁt,
compared with option A. For example, at a l of
$12,000, the mean net beneﬁts for options A, C, and
D were $9844, $9841, and $9840, and the variances
were $7426, $10,967, and $11,027. Thus, as the
probability distributions surrounding the mean net
beneﬁt of options C/D were more spread out than for
option A within a particular iteration, despite the
marginally lower mean values of net beneﬁt for C/D,
there was a higher probability of a higher net beneﬁt
being drawn for options C/D than for option A.
When the level of variation was reduced, the distri-
butions became more tightly centered around the
mean, and within a particular iteration, option A had
a higher probability of having a higher net beneﬁt
than options C/D (see CEACs in Fig. 3b). Increasing
the level of variation had the opposite effect on the
CEACs (Fig. 4b), as those options that had a rela-
tively high level of variation (e.g., options C and D)
had the highest net beneﬁt in a greater proportion of
iterations, and thereby a greater probability of being
cost-effective than in the base-case, at the expense of
the those options that had a relatively low level of
variation (e.g., options A and B).
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Reducing the level of variation increased the pro-
portion of iterations where optimal options had the
highest net beneﬁt. Thus, as optimal options tended to
have the highest probability of being cost-effective, the
CEAF was more often equivalent to the uppermost
CEAC, and the probability of making a wrong deci-
sion tended to be lower (Fig. 3b). This, combined with
the lower level of variation in net beneﬁt, which
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Figure 2 Replication of the analysis by Goeree et al. [1], with the assumption that the costs and effects between options were independent. Results are
presented in terms of the cost-effectiveness plane (a), cost-effectiveness acceptability curves, cost-effectiveness acceptability frontier, and expected value
of perfect information (EVPI) (b).
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reduced the consequences of making a wrong decision,
meant that the EVPI was also lower when the variation
was reduced (Fig. 3b). However, the converse occurred
when the level of variation increased—the CEAF was
less frequently equivalent to the uppermost CEAC, the
probability of making the wrong decision tended to
increase, as did the consequences of making a wrong
decision, and in turn the EVPI also increased (Fig. 4b).
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Figure 3 Replications of the analysis by Goeree et al. [1] with the assumption that the variance associated with the mean cost and mean effect of each
option was one-ﬁfth of that in the base-case analysis. Results are presented in terms of the cost-effectiveness plane (a), cost-effectiveness acceptability
curves, cost-effectiveness acceptability frontier, and expected value of perfect information (EVPI) (b).
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Discussion
In order to show how to present the optimal decision
and the uncertainty associated with that decision when
assessing multiple options, we replicated the analysis
of a previous paper and performed sensitivity analysis
on the assumptions of that analysis. In doing so, we
demonstrated that CEACs can sometimes show 1) that
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Figure 4 Replications of the analysis by Goeree et al. [1] with the assumption that the variance associated with the mean cost and mean effect of each
option was ﬁve times that in the base-case analysis. Results are presented in terms of the cost-effectiveness plane (a), cost-effectiveness acceptability
curves, cost-effectiveness acceptability frontier, and expected value of perfect information (EVPI) (b).
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options that are subject to extended dominance have
the highest probability of being cost-effective; or 2)
that optimal options do not have the highest probabil-
ity of being cost-effective for any value of the cost-
effectiveness threshold. Thus, we have shown that
CEACs should not be used to determine the optimal
decision, as previously suggested by Kamath et al. [7].
In addition, we have explained that these two effects
can arise because of the correlation structure and dif-
ferences in the level of variation between multiple
options. Furthermore, in order to present the optimal
decision and the level of uncertainty associated with
that decision, we have demonstrated that the CEAF,
along with the EVPI, should be calculated. Finally,
it has also been shown that it is, for example, possible
for uncertainty to increase (as assessed by the EVPI)
when the probability of the optimal option being cost-
effective also increases.
Implications
We have demonstrated, as previously suggested
[17,21,22], that instead of using the CEAC to estimate
which option is optimal, the sole purpose of presenting
the CEAC is to demonstrate the level of uncertainty
associated with an option. Moreover, we have also
shown that if our objective is to maximize the expected
net beneﬁt regardless of the level of uncertainty, as
argued previously by Claxton [15], then this can result
in choosing options where we know there is a high
probability of making a wrong decision. For example,
in the study by Goeree et al. [1], at a l of $12,000,
option A was optimal despite the fact that the prob-
ability of this being the wrong decision exceeded 80%
(see Fig. 1c). The ﬁrst implication of our results, there-
fore, is that when presenting the results of cost-
effectiveness analyses, it should be made clear that the
CEACs are presented in order to depict the level of
uncertainty and not the optimal decision.
We also demonstrated that though the cost-
effectiveness plane can depict the optimal decision, it
cannot depict the level of uncertainty, because it is
insensitive to the correlation structure between
options. Thus, the second implication of our results is
that in order to simultaneously present the optimal
decision, along with the uncertainty associated with
that decision, the CEAF should be plotted. Indeed, the
only time it may be appropriate to present uncertainty
on the cost-effectiveness plane is when two options are
being compared. This arises because in contrast to the
situation for multiple options, the incremental cost and
incremental effects can be plotted, thus directly reveal-
ing the correlation structure.
The CEAF is, however, constructed from the CEAC
of the optimal option(s), and therefore only depicts
uncertainty through the probability of not selecting the
most cost-effective option. The CEAF does not portray
the consequences of the decision; as such, it provides
only a ﬁrst step in determining the value of further
research. Indeed, in order to determine the latter, the
third implication of our research is that the EVPI
should be calculated. Moreover, because the correla-
tion structure between options was shown to affect
the consequences of making the wrong decision, this
shows that the EVPI can provide further information
that is not captured by the cost-effectiveness plane or
the CEAF.
Strengths and Weaknesses
A crucial assumption within this paper is that optimal
decisions will be made when options with the highest
expected net beneﬁt are implemented (i.e., when ben-
eﬁts are maximized for a given cost). However, Coast
[5] has argued that such an objective does not comply
with how society would wish to allocate scarce health-
care resources, because for example, it ignores the
notion of equity. To reﬂect this, the objective could be
adapted to include an equity weighting, but this would
not change the fact that it is possible for an optimal
option (unless optimal is deﬁned in terms of probabil-
ity) not to have the highest probability of being cost-
effective, and thus the CEAC should not be used to
determine the optimal allocation of resources.
We are only aware of one previous possible expla-
nation as to why an optimal option may not have the
highest probability of being cost-effective, namely, that
the incremental net beneﬁt was positively skewed [17].
However, as this was not the case in the Goeree et al.
[1] analysis, positive skewness could not account for
why it had previously been shown that an option that
was subject to extended dominance had, at certain
l-values, the highest probability of being cost-effective,
nor could it account for why an option that was cost-
effective never had the highest probability of being
cost-effective [1]. Thus, the main strength of this article
is in demonstrating that these instances can be brought
about by particular correlation structures, or by differ-
ences in the relative levels of variance between multiple
options. Our results are also therefore supported by
others [29,30] who have shown that the correlation
structure between the costs and effects of different
options can greatly inﬂuence the level of uncertainty.
By constructing a template, we have further demon-
strated that the shapes of the CEACs, the CEAF, and
the EVPI are highly dependent upon assumptions
made about the correlation structure and the relative
levels of the variance.
The template we created was based on the assump-
tion of multivariate normality; thus, it may not be
appropriate to use it in replicate studies where there is
substantial departure from this distribution. That said,
it is possible to use the Cholesky decomposition tech-
nique to incorporate correlations between other types
of distributions, as has been explained by Briggs et al.
[20]. Moreover, the template can be similarly adapted
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to extract the mean cost and mean effect from other
probabilistic models, and thereby construct the
CEACs, CEAF, and EVPI for other studies.
Conclusion
The cost-effectiveness plane has limited use in repre-
senting uncertainty in the multiple-option case as it
cannot represent correlation between the options,
which can play a very important role. CEACs can
represent decision uncertainty, but should not be used
to determine the optimal decision. Instead, the CEAF
shows the optimal choice and this can be augmented
using the EVPI plot to show the potential gains of
further research to reduce uncertainty.
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